CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenues:
Revenues	$ 1,711.8	$ 1,511.5
Expenses:
Research and development	641.8	498.6
Selling, general, and administrative	410.8	330.8
Total expenses	1,231.8	944.3
Income from operations	480.0	567.2
Other income (expense):
Other income (expense), net	73.8	24.6
Interest expense	(7.7)	(6.4)
Total other income (expense)	66.1	18.2
Income before income taxes	546.1	585.4
Income tax expense	(85.0)	(107.4)
Net income	$ 461.1	$ 478.0
Net income per share - basic (in dollars per share)	$ 4.23	$ 4.44
Net income per share - diluted (in dollars per share)	$ 3.99	$ 4.16
Weighted average shares outstanding - basic (in shares)	108.9	107.6
Weighted average shares - diluted (in shares)	115.5	114.9
Statements of Comprehensive Income
Net income	$ 461.1	$ 478.0
Other comprehensive income (loss), net of tax:
Unrealized gain (loss) on debt securities	16.1	(11.1)
Unrealized (loss) gain on cash flow hedges	(1.0)	1.4
Comprehensive income	476.2	468.3
Product
Revenues:
Revenues	1,104.4	987.9
Expenses:
Cost of goods sold	70.9	69.2
Collaboration and contract manufacturing
Expenses:
Cost of goods sold	108.3	45.7
Sanofi | Product and service, other
Revenues:
Revenues	246.4	189.5
Bayer | Product and service, other
Revenues:
Revenues	276.2	247.9
Other | Product and service, other
Revenues:
Revenues	$ 84.8	$ 86.2